MDA-MB-231-luc Orthotopic Mouse Model Service for Breast Cancer

The MDA-MB-231-luc orthotopic model delivers a firefly luciferase–tagged, triple-negative breast cancer platform that enables real-time visualization of aggressive primary tumor growth and spontaneous metastatic dissemination to lung, bone, and brain in an immunodeficient host. Alfa Cytology constructs and validates this image-guided xenograft system from authenticated reporter cell banks through orthotopic mammary fat pad implantation, longitudinal IVIS monitoring, and multi-organ endpoint analysis—providing a preclinical pipeline optimized for screening anti-metastatic compounds, testing TNBC-targeted biologics, and dissecting the epithelial-to-mesenchymal transition dynamics that drive therapeutic resistance.

Overview of MDA-MB-231-luc Orthotopic Mouse Model for Breast Cancer

MDA-MB-231 is a human breast adenocarcinoma cell line originally established in 1973 at the M.D. Anderson Cancer Center from a pleural effusion specimen collected from a 51-year-old Caucasian woman with invasive ductal carcinoma. Genomically, the line clusters within the basal B molecular subtype of triple-negative breast cancer: it is estrogen receptor negative, progesterone receptor negative, and HER2 negative, while harboring oncogenic driver mutations in TP53, KRAS, and BRAF that collectively sustain constitutive proliferation, genomic instability, and mesenchymal plasticity. The cells exhibit a pronounced epithelial-to-mesenchymal transition phenotype—characterized by loss of E-cadherin, gain of N-cadherin and vimentin, and enhanced migratory capacity in vitro—which translates into robust invasive and metastatic behavior in vivo. When implanted orthotopically into the mammary fat pad of immunodeficient mice, MDA-MB-231 forms aggressive primary tumors that spontaneously metastasize to regional lymph nodes and, via hematogenous dissemination, colonize distant organs including lung, bone, and brain with a temporal pattern that mirrors late-stage human TNBC progression.

Fig 1. Tumor volume/loading measurement with a caliper started on day 10 after xenograft implantation and then was measured 2x a week until the end of the experiment. (Cheng, Robert YS, et al., 2020)

The luciferase-engineered derivative, MDA-MB-231-luc, stably expresses firefly luciferase 2 (Luc2) under a constitutive promoter, enabling quantitative bioluminescence imaging that detects viable tumor cell mass with single-cell sensitivity in ex vivo organ lysates. This reporter integration transforms the model into a dynamic, non-invasive pharmacodynamic instrument: primary tumor engraftment is detectable within days of implantation, exponential growth is tracked weekly via photon flux quantification, and micrometastatic seeding in secondary organs is visualized long before macroscopic lesions become palpable. The model has been further refined through the selection of organotropic subclones—MDA-231BO (bone-seeking) and MDA-231BR (brain-seeking)—by serial in vivo passaging and ex vivo culture of metastatic deposits, yielding variants with preferential homing tropisms that are invaluable for tissue-specific metastasis research. For preclinical teams developing anti-metastatic agents, bisphosphonate conjugates, or blood-brain barrier–penetrant therapies, the MDA-MB-231-luc orthotopic xenograft offers an unparalleled combination of aggressive TNBC biology, quantitative imaging resolution, and multi-organ metastatic fidelity.

Cell Line Information: MDA-MB-231-luc

MDA-MB-231-luc is a firefly luciferase–expressing derivative of the parental MDA-MB-231 human triple-negative breast adenocarcinoma line, engineered for quantitative bioluminescence imaging of tumor burden and metastatic dissemination. The parental line is the most widely utilized TNBC model in oncology research and has been extensively profiled across the Cancer Cell Line Encyclopedia, TCGA, and GDSC pharmacogenomic databases. The table below summarizes the essential characteristics of MDA-MB-231-luc as applied in orthotopic xenograft preclinical research.

Our Services

Alfa Cytology maintains MDA-MB-231-luc under continuous antibiotic selection to preserve luciferase expression fidelity, with each batch authenticated by STR profiling against the ATCC reference standard, confirmed negative for mycoplasma by PCR, and validated for single-cell BLI sensitivity prior to in vivo release. Our surgical and imaging teams operate in a barrier-facility environment optimized for immunodeficient xenograft work, ensuring high tumor take rates, reproducible metastatic timelines, and quantitative photon-flux datasets that support robust anti-metastatic and TNBC-targeted preclinical development.

Workflow of MDA-MB-231-luc Orthotopic Mouse Model Construction

Establishing the MDA-MB-231-luc orthotopic model requires precise execution across cell authentication, matrix-assisted surgical implantation, longitudinal bioluminescence surveillance, and multi-organ metastasis endpoint analysis. Because this line exhibits rapid proliferation and aggressive metastatic behavior, the window between implantation and therapeutic intervention is narrower than in slower-growing models, necessitating tightly coordinated scheduling. The workflow below integrates luciferase validation, orthotopic delivery, weekly IVIS imaging, and terminal ex vivo organ BLI into a streamlined protocol optimized for anti-metastatic drug screening and TNBC pharmacology studies.

1. Cell Authentication & Luciferase Validation: MDA-MB-231-luc cells are thawed from a master cell bank verified by STR profiling against the ATCC reference standard and confirmed negative for mycoplasma by PCR. Cells are expanded under antibiotic selection to maintain reporter expression. Prior to in vivo use, luciferase activity is validated by D-luciferin substrate assay on a luminometer, and single-cell detection sensitivity is confirmed by serial dilution in organ lysate matrices to ensure downstream ex vivo metastasis quantification is interpretable.
2. Cell Harvest & Matrix Preparation: On the day of surgery, subconfluent MDA-MB-231-luc cells are detached with trypsin-EDTA, washed twice in sterile PBS, and counted via hemocytometer with trypan blue viability assessment. The final suspension is prepared at 2–6 × 10⁷ cells/ml in ice-cold PBS and mixed 1:1 (v/v) with chilled, phenol red–free basement membrane matrix to achieve a final concentration of 1–3 × 10⁶ cells per 100 µl. The mixture is kept on ice until injection to prevent premature gelation.
3. Animal Preparation & Anesthesia: Female NOD-SCID or NSG mice aged 4–6 weeks are housed in individually ventilated cages within a barrier facility and acclimatized for 5–7 days. On the procedure day, mice are anesthetized with isoflurane (2–3% in medical oxygen) via precision vaporizer and nose cone. The lower abdominal surgical field—centered on the 4th inguinal mammary gland—is shaved, depilated if necessary, and sterilized sequentially with povidone-iodine and 70% ethanol.
4. Orthotopic Mammary Fat Pad Implantation: A 100 µl suspension containing 1–3 × 10⁶ MDA-MB-231-luc cells in basement membrane matrix is drawn into a ½ cc insulin syringe fitted with a 25 G needle. The needle is inserted tangentially into the 4th inguinal mammary fat pad, and the cell-matrix mixture is deposited slowly within the glandular stroma. The needle is held in place for 10–15 seconds post-injection to minimize reflux. The skin is closed with surgical adhesive or a single wound clip, and mice are recovered on a heated pad under continuous observation until fully ambulatory.
5. Baseline & Longitudinal Bioluminescence Imaging: Beginning at day 3–5 post-implantation, mice are imaged weekly via an in vivo imaging system (IVIS or equivalent). Each mouse receives an intraperitoneal injection of D-luciferin (150 mg/kg body weight), is anesthetized with isoflurane, and positioned for dorsal and ventral image acquisition. Regions of interest are drawn over the mammary gland to quantify primary tumor photon flux and establish baseline signal intensity. Signal saturation thresholds are monitored to ensure quantification remains within the linear dynamic range of the CCD camera.
6. Tumor Monitoring & Therapeutic Intervention: Tumor dimensions are measured twice weekly with digital calipers, and volume is calculated using the modified ellipsoid formula (length × width² × 0.5). Body weights and clinical scores are recorded at each interval. Once tumors reach a protocol-defined size—commonly 100–200 mm³ or a predetermined BLI photon flux threshold—mice are randomized into vehicle control and treatment cohorts. Investigational agents (e.g., anti-metastatic compounds, TNBC-targeted biologics, bisphosphonate conjugates, or immuno-oncology modalities) are administered according to the study design.
7. Metastasis Surveillance & Circulating Tumor Cell Assessment: In parallel with primary tumor monitoring, weekly BLI is scrutinized for thoracic and abdominal signal foci indicative of lung or liver micrometastatic seeding. For studies requiring CTC quantification, terminal blood draws are processed for luciferase activity assay, enabling enumeration of circulating tumor cells at single-cell resolution. Ex vivo organ imaging at necropsy confirms metastatic burden in lung, bone, brain, liver, and lymph nodes with photon flux normalization to tissue weight.
8. Terminal Endpoint & Multi-Organ Molecular Analysis: At study termination—when vehicle tumors approach institutional size limits (typically ~2,000 mm³ or 6–8 weeks post-implantation)—mice are euthanized and subjected to ex vivo BLI of harvested organs. Primary tumors are excised en bloc, weighed, and photographed. Tissue is snap-frozen for Western blot or RNA analysis, fixed in 10% neutral buffered formalin for paraffin embedding and H&E staining, and subjected to immunohistochemistry for Ki67, E-cadherin, N-cadherin, vimentin, phospho-ERK, and cleaved caspase-3. Bone metastases are confirmed by micro-CT or histomorphometry when indicated.

Fig 2. MDA-MB-231-luc Orthotopic Mouse Model construction workflow.

Case Study-MDA-MB-231-luc Orthotopic Mouse Model Development

In a recent preclinical engagement, Alfa Cytology established an orthotopic MDA-MB-231-luc xenograft to evaluate the anti-metastatic efficacy of a novel bisphosphonate–drug conjugate targeting the bone microenvironment. Following mammary fat pad implantation in NOD-SCID mice, tumor-bearing animals were randomized into vehicle and treatment cohorts once primary tumors reached approximately 150 mm³. The investigational conjugate was administered weekly over a 5-week treatment window, with longitudinal IVIS imaging performed weekly to track primary tumor photon flux and detect early thoracic signal indicative of pulmonary metastatic seeding. While primary tumor growth was modestly inhibited in the treated group, ex vivo BLI at necropsy revealed a marked reduction in bone metastatic burden and a significant decrease in circulating tumor cell counts compared to vehicle controls. Immunohistochemical analysis of residual primary tumors showed elevated E-cadherin and reduced vimentin staining in the treatment arm, suggesting partial reversal of the mesenchymal phenotype. These preclinical findings provided mechanistic rationale for advancing the conjugate into bone-metastasis–focused pharmacology studies, illustrating the translational utility of the MDA-MB-231-luc model in capturing both primary tumor dynamics and distant organ tropism.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your MDA-MB-231-luc orthotopic program means partnering with a CRO that has built its infrastructure around the unique demands of aggressive, metastatic human xenografts. We understand that rapid tumor kinetics, quantitative BLI sensitivity, and multi-organ endpoint fidelity are non-negotiable prerequisites for meaningful anti-metastatic preclinical data.

• MDA-MB-231-luc master cell banks are maintained under continuous antibiotic selection with periodic STR authentication against the ATCC reference, mycoplasma screening, and pre-batch single-cell BLI sensitivity validation to ensure reporter fidelity and quantitative reliability.
• Our barrier-facility vivarium and surgical suites operate under stringent pathogen-free protocols with continuous health surveillance, minimizing infection risk in immunodeficient hosts and preserving data integrity across rapid-growth studies.
• Surgical teams are proficient in orthotopic mammary fat pad implantation with basement membrane matrix, achieving high tumor take rates for MDA-MB-231 despite its aggressive proliferation kinetics and mesenchymal morphology.
• In-house IVIS or equivalent bioluminescence imaging platforms are calibrated for quantitative photon-flux measurement with standardized ROI analysis, background subtraction, and linear dynamic range monitoring to ensure interpretable longitudinal data.
• Multi-organ metastasis surveillance capabilities include weekly in vivo BLI for thoracic and abdominal foci, terminal ex vivo organ photon flux quantification, circulating tumor cell enumeration by luciferase assay, and bone lesion confirmation by micro-CT or histomorphometry.
• Flexible study designs accommodate single-agent anti-metastatic screening, combination therapy arms, bisphosphonate conjugate evaluation, sequential dosing schedules, and long-term acquired resistance modeling with interim CTC and metastasis burden assessments.
• Terminal analysis packages integrate EMT marker IHC (E-cadherin, N-cadherin, vimentin), proliferation and apoptosis indices, phospho-ERK signaling readouts, and RNA-seq profiling—providing mechanistic depth alongside standard efficacy and metastasis endpoints.
• All protocols are developed and executed under IACUC oversight with AAALAC-aligned welfare standards, producing audit-ready documentation and imaging archives suitable for IND-enabling submissions, investor due diligence, and peer-reviewed publication.

Contact Us

If your preclinical pipeline demands an aggressive, image-guided triple-negative breast cancer model with built-in metastasis tracking and multi-organ endpoint resolution, Alfa Cytology's MDA-MB-231-luc orthotopic service delivers the quantitative rigor and biological fidelity your program requires. Contact us today to discuss your anti-metastatic study design, review our MDA-MB-231-luc quality control and BLI validation protocols, and receive a customized proposal with CTC enumeration, bone metastasis assessment, and multi-parameter molecular endpoint packages tailored to your TNBC-targeted development strategy.

For research use only. Not intended for any clinical use.